Every year in biopharma brings its share of grueling defeats, and 2025 was no different, especially for companies targeting ...

Over the past decade, a shift has been occurring in biopharma R&D. Despite great advancements in drug technologies and our understanding of diseases, it is getting harder to develop new drugs and ...

AI’s true promise is turning clinical development from a bottleneck into a throughput engine for human health. Drug discovery ...

The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute ...

Expedited Development Enabled by RMAT and Breakthrough Therapy StatusClinical Trial Initiation in 2026, FDA Approval Target ...

Claim 70% Off TipRanks This Holiday SeasonUnlock hedge-fund level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis ...

The clinical study is divided into two parts: a Phase I dose escalation stage and a Phase IIa dose expansion and optimisation ...

Veteran gastroenterologist and clinical development leader with deep expertise driving global Phase 2/3 programs across immunology, neurology, and gastrointestinal disease Carlsbad, CA, Dec. 02, 2025 ...

The FDA’s emerging framework represents more than a regulatory update; it is a paradigm shift toward human-relevant, ...

Advances in our understanding of cancer biology have led to the discovery of a spectrum of new therapeutic targets. However, despite remarkable progress in the identification and characterization of ...

In Q3 2025, Viking Therapeutics highlighted significant progress in its obesity pipeline, particularly for the dual GLP-1/GIP ...